The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001020370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
22/07/2026
Date registered
Help: Date registered
18/08/2026
Date last updated
Help: Date last updated
18/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
18/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1, First-in-human Single Photon Emission Computed Tomography (SPECT) Imaging Study to Assess [203Pb]Pb-AB102 in Participants with Advanced Solid Tumours
Scientific title
A Phase 1, Open-label, First-in-human, Single Photon Emission Computed Tomography (SPECT) Imaging Study to Assess the Biodistribution of [203Pb]Pb-AB102 in Participants with Advanced Solid Tumours
Additional trial identifiers [1] 317983 0
AB102-25-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Triple Negative Breast Cancer 342961 0
Squamous Cell Carcinoma's 343203 0
Condition category
Condition code
Cancer 339077 339077 0 0
Breast
Cancer 339161 339161 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention Drug #1: [203Pb]Pb-AB102

Participants will receive a single intravenous (IV) solus bolus injection of [203Pb]Pb-AB102. The radioactivity is 315-400MBq and 10ml in volume, the dose is the same for all participants (360MBq) and may be adjusted at Sponsor discretion based off scan quality. The study imaging agent will be administered by authorised and appropriately trained site personnel in the Nuclear Medicine department, under the supervision of the Investigator. [203Pb]Pb-AB102 is administered as a slow IV injection (not exceeding 15 minutes) during Imaging Period 1 (Day 1). As the study intervention is administered on-site by qualified personnel, adherence is ensured through direct administration and source documentation. The protocol requires recording of the date, time and dose administered. Drug administration records are maintained to document compliance.

SPECT/CT Imaging

The SPECT/CT component involves acquisition of SPECT images together with low-dose CT images following administration of [203Pb]Pb-AB102. The imaging is performed to evaluate the biodistribution and tumour lesion uptake of the investigational imaging agent. Participants undergo one [203Pb]Pb-AB102 imaging period following a single administration of the investigational imaging agent, the scans are 1.5 hours, 8 hours and 24 hours after injection. The imaging period includes 3 SPECT/CT acquisitions over two days following injection. SPECT/CT imaging is performed at the participating site's Nuclear Medicine Department using standard clinical SPECT/CT imaging equipment. The SPECT/CT scans will be performed by appropriately qualified Nuclear Medicine Technologists and Nuclear Medicine staff in accordance with local site procedures and under the supervision of the Investigator and Nuclear Medicine Physician. As all imaging procedures are conducted on-site under direct supervision, adherence is ensured through completion of required imaging procedures. Imaging completion and acquisition details are documented in source records and the eCRF.

Intervention Drug #2 – [68Ga]Ga-AB101

Participants will receive a single intravenous (IV) administration of [68Ga]Ga-AB101 at 2MBq/kg up to a maximum of 200MBq at 10ml. This component of the trial occurs at least 5 days after the [203Pb]Pb-AB102 administration, participation is optional and determined by the participant, it requires an additional consent form to be signed as part of the trial. The study imaging agent will be administered by authorised and appropriately trained site personnel in the Nuclear Medicine Department, under the supervision of the Principal Investigator. [68Ga]Ga-AB101 is administered as a slow IV injection (not exceeding 15 minutes) during the Imaging Period 2 (after the SPECT scan). As the study intervention is administered on-site by qualified study personnel, adherence is ensured through direct administration and source documentation. The date, time and dose administered are recorded in source documents and the electronic case report form (eCRF), and drug administration records are maintained to document compliance.

PET/CT Imaging

The PET/CT component involves acquisition of PET images together with CT images following administration of [68Ga]Ga-AB101. The imaging is performed to identify and evaluate P-cadherin-expressing lesions and to assess tumour uptake of the investigational imaging agent. Participants undergo one [68Ga]Ga-AB101 PET/CT imaging period following a single administration of [68Ga]Ga-AB101, the scan is 1 hour after injection. The PET/CT imaging period occurs on a single study day and may include protocol-specified image acquisitions associated with that visit. PET/CT imaging is performed at the participating site's Nuclear Medicine Department using standard clinical PET/CT imaging equipment. The PET/CT scans will be performed by appropriately qualified Nuclear Medicine Technologists/Radiographers and Nuclear Medicine staff in accordance with local site procedures and under the supervision of the Investigator and Nuclear Medicine Physician, where applicable. As all imaging procedures are conducted on-site under direct supervision, adherence is ensured through participant attendance at scheduled imaging visits and completion of required imaging procedures. Imaging completion and acquisition details are documented in source records and the eCRF.
Intervention code [1] 334855 0
Diagnosis / Prognosis
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346313 0
To evaluate the biodistribution and lesion uptake of [203Pb]Pb-AB102 (composite endpoint)
Timepoint [1] 346313 0
Outcome measured at 1.5h, 8h and 24h post injection
Secondary outcome [1] 465385 0
To determine the safety and tolerability profile of [203Pb]Pb-AB102 following a single administration. This will be assessed as a composite outcome.
Timepoint [1] 465385 0
Adverse events are monitored from Screening to Safety Follow Up (5 days post injection) and are assessed via ECG, physical examination, vital signs, blood and urine tests.
Secondary outcome [2] 465856 0
To evaluate the pharmacokinetics of [203Pb]Pb-AB102
Timepoint [2] 465856 0
Predose, 15 min, 30 min, 1.5h, 8h and 24h post dose
Secondary outcome [3] 466186 0
To evaluate the relationship between [203Pb]Pb-AB102 and [68Ga]Ga-AB101 uptake in lesions in participants who undergo the optional [68Ga] imaging assessment
Timepoint [3] 466186 0
[68Ga]Ga-AB101 PET/CT (1h) and [203Pb]Pb-AB102 SPECT/CT (1.5h, 4h, 24h) Imaging

Eligibility
Key inclusion criteria
Locally advanced or metastatic carcinoma with histological confirmation of
triple-negative breast cancer (TNBC) or squamous cell carcinoma including but not
limited to squamous non-small cell lung cancer (sqNSCLC), oesophageal squamous
cell carcinoma (OSCC), head and neck squamous cell carcinoma (HNSCC), and other
squamous cell carcinomas such as those arising from the skin, vulva, penis, cervix,
and anal canal.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Concurrent participation in the active treatment part of another clinical study with
IMP(s). Any condition which in the opinion of the Investigator would preclude the
participants’ study participation, place them at undue risk, impair their ability to
comply with the protocol requirements, or impair the scientific validity of the trial.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 322533 0
Commercial sector/Industry
Name [1] 322533 0
ARTBIO Pty Ltd
Country [1] 322533 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
ARTBIO Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325456 0
None
Name [1] 325456 0
Address [1] 325456 0
Country [1] 325456 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321015 0
Bellberry Human Research Ethics Committee K
Ethics committee address [1] 321015 0
Ethics committee country [1] 321015 0
Australia
Date submitted for ethics approval [1] 321015 0
05/05/2026
Approval date [1] 321015 0
07/07/2026
Ethics approval number [1] 321015 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152374 0
Dr Rodney Hicks
Address 152374 0
Melbourne Theranostic and Innovation Centre, Level 8, 14–20 Blackwood Street, North Melbourne VIC 3051
Country 152374 0
Australia
Phone 152374 0
+61 03 9454 5800
Fax 152374 0
Email 152374 0
Contact person for public queries
Name 152375 0
William Lindeman
Address 152375 0
ARTBIO Pty Ltd, Suite 1, Level 3 62 Lygon Street Carlton South VIC 3053 Australia
Country 152375 0
Australia
Phone 152375 0
+61 431 382 819
Fax 152375 0
Email 152375 0
Contact person for scientific queries
Name 152376 0
Rodney Hicks
Address 152376 0
Melbourne Theranostic and Innovation Centre, Level 8, 14–20 Blackwood Street, North Melbourne VIC 3051
Country 152376 0
Australia
Phone 152376 0
+61 03 9454 5800
Fax 152376 0
Email 152376 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.